Evoke Pharma, Inc. (NASDAQ: EVOK) shares fell slightly Wednesday at the open. The company, a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from the first patient-centered survey related to GIMOTI.
Following the series of market insights gathered on the perception of GIMOTI by prescribers (primarily gastroenterologists, nurse practitioners/physicians assistants and some primary care doctors), a research study was initiated to capture patient responses on their individual gastroparesis (GP) experiences and feedback on current treatment options.
In April 2022, EVERSANA conducted the patient segment of the GIMOTI Awareness, Trial, Usage (ATU) Study, a quantitative survey designed to measure patient awareness, trial, and product usage of GIMOTI. This first wave of the ATU patient survey was centered around three major themes: symptoms and diagnosis, feedback on existing medications, and their experiences with GIMOTI.
The blinded survey was completed with 110 patients who represented a diverse range of age, gender, racial background, geographic locations and diabetes subtypes. Majority of the respondents were between 19-65 years old. The respondents were predominantly Caucasian with a higher sample of female patients, consistent with the demographics of GP patients generally.
The tests found that roughly 50% of users do not see any symptom improvement from existing oral treatment options (liquid or tablet forms) Of all respondents, 38% discontinued their GP medications primarily due to either side effects or lack of symptom improvement.
EVOK shares dipped 0.7 cents, or 2.1%, to 32 cents
